SARASOTA, Fla. (April 2, 2025) – While ovarian cancer is relatively rare, it is a stealthy disease, with no noticeable symptoms until it reaches an advanced, less treatable stage.
Standard treatment in these later stages typically involves surgery followed by a course of platinum-based chemotherapy. Recurrence is common in this patient population, and patients often build up resistance to the platinum-based therapy.
To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute has joined 30 research sites testing the efficacy of an experimental immunotherapeutic drug, Olvi-Vec, used in combination with FDA-approved platinum-based chemotherapy and targeted therapy drug bevacizumab.
“Olvi-vec is an experimental biologic that works by selectively infecting and killing cancer cells while sparing normal tissue,” said Beverly Long, MD, principal investigator of the Sarasota
Memorial study and gynecological oncologist with Sarasota Memorial’s First Physicians Group and Brian D. Jellison Cancer Institute. “We hope this study yields promising results and ultimately a new treatment that improves outcomes for late-stage ovarian cancer patients whose cancer does not respond to current therapies.”
Olvi-Vec has been studied in multiple clinical trials to evaluate its safety and efficacy in treating ovarian cancer. In previous Phase 2 trials, Olvi-Vec met the studies’ safety and efficacy endpoints, and in select patients showed evidence of clinical reversal of platinum resistance or refractoriness.
Approximately 186 patients will be enrolled in the randomized Phase 3 OnPrime/GOG-3076 trial sponsored by Genelux, in collaboration with GOG Partners, a GOG Foundation, Inc. program, with a study duration of about three years, including treatment and follow-up care.
Criteria to enroll in the study include:
- High-Grade serous, endometrioid, or clear-cell ovarian cancer.
- Platinum-resistant or - refractory disease
- Received prior bevacizumab (or biosimilar) treatment.
- Received a minimum of 3 prior lines of systematic therapy with no maximal limit.
- Performance status of ECOG is at 0 or 1, and life-expectancy of at least 6 months.
For more information about this or other clinical trials, contact the Sarasota Memorial Research Institute at (941) 917-2225.
About the Sarasota Memorial Research Institute
Sarasota Memorial Research Institute (SMRI) provides advanced research services and a highly qualified staff that advances the latest treatment options for patients in our community. Located on Sarasota Memorial Health Care System’s Sarasota campus, the Institute provides the knowledge, expertise, and infrastructure essential to evaluate and manage innovative drug, device, registry, and biospecimen clinical trials across a wide spectrum of disease processes, including cardiology, infectious disease, gastroenterology, neurology, oncology, pulmonology, urology, vascular, and more. For information about clinical studies or participating in clinical trials, contact the Sarasota Memorial Research Institute at (941) 917-2225.
For more information about the GOG Foundation, Inc. and GOG Partners Program, please contact: Jenna Cummins, CMP, Executive Director of Business Development jcummins@gog.org or visit www.gog.org.